Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis

被引：0

作者：

Yuki Tahata

Hayato Hikita

Satoshi Mochida

Nobuyuki Enomoto

Norifumi Kawada

Masayuki Kurosaki

Akio Ido

Daiki Miki

Hitoshi Yoshiji

Yasuhiro Takikawa

Ryotaro Sakamori

Yoichi Hiasa

Kazuhiko Nakao

Naoya Kato

Yoshiyuki Ueno

Hiroshi Yatsuhashi

Yoshito Itoh

Ryosuke Tateishi

Goki Suda

Taro Takami

Yasunari Nakamoto

Yasuhiro Asahina

Kentaro Matsuura

Taro Yamashita

Tatsuya Kanto

Norio Akuta

Shuji Terai

Masahito Shimizu

Satoshi Sobue

Tomokatsu Miyaki

Akihiro Moriuchi

Ryoko Yamada

Takahiro Kodama

Tomohide Tatsumi

Tomomi Yamada

Tetsuo Takehara

机构：

[1] Osaka University Graduate School of Medicine,Department of Gastroenterology and Hepatology

[2] Saitama Medical University,Department of Gastroenterology and Hepatology

[3] University of Yamanashi,First Department of Internal Medicine, Faculty of Medicine

[4] Osaka City University,Department of Hepatology, Graduate School of Medicine

[5] Musashino Red Cross Hospital,Department of Gastroenterology and Hepatology

[6] Kagoshima University Graduate School of Medicine and Dental Sciences,Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences

[7] Hiroshima University,Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences

[8] Nara Medical University,Department of Gastroenterology

[9] Iwate Medical University,Division of Hepatology, Department of Internal Medicine

[10] Ehime University Graduate School of Medicine,Department of Gastroenterology and Metabology

[11] Nagasaki University of Graduate School of Biomedical Sciences,Department of Gastroenterology and Hepatology

[12] Chiba University,Department of Gastroenterology, Graduate School of Medicine

[13] Yamagata University,Department of Gastroenterology, Faculty of Medicine

[14] National Hospital Organization Nagasaki Medical Center,Clinical Research Center

[15] Kyoto Prefectural University of Medicine,Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science

[16] The University of Tokyo,Department of Gastroenterology, Graduate School of Medicine

[17] Hokkaido University,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[18] Yamaguchi University Graduate School of Medicine,Department of Gastroenterology and Hepatology

[19] University of Fukui,Second Department of Internal Medicine, Faculty of Medical Sciences

[20] Tokyo Medical and Dental University,Department of Gastroenterology and Hepatology, Department of Liver Disease Control

[21] Nagoya City University Graduate School of Medical Sciences,Department of Gastroenterology and Metabolism

[22] Kanazawa University Hospital,Department of General Medicine

[23] National Center for Global Health and Medicine,The Research Center for Hepatitis and Immunology

[24] Toranomon Hospital,Department of Hepatology

[25] Niigata University,Division of Gastroenterology and Hepatology, Graduate School of Medicine and Dental Sciences

[26] Gifu University Graduate School of Medicine,Department of Gastroenterology/Internal Medicine

[27] Kasugai Municipal Hospital,Department of Gastroenterology

[28] Toyokawa City Hospital,Department of Gastroenterology

[29] National Hospital Organization Kagoshima Medical Center,Department of Gastroenterology

[30] Osaka University Hospital,Department of Medical Innovation

来源：

Journal of Gastroenterology | 2022年 / 57卷

关键词：

Liver cirrhosis; Prognosis; Hepatocellular carcinoma; Decompensated cirrhotic event; Survival;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：120 / 132

页数：12

共 100 条

[1]

Afdhal N(2014)Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 1889-1898

[2]

Zeuzem S(2015)Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection N Engl J Med 373 2599-2607

[3]

Kwo P(2017)Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial Lancet Infect Dis 17 1062-1068

[4]

Feld JJ(2018)Liver fibrosis is associated with corrected QT prolongation during Ledipasvir/Sofosbuvir treatment for patients with chronic hepatitis C Hepatol Commun 2 884-892

[5]

Jacobson IM(2019)Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): a nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group Hepatol Res 49 1114-1120

[6]

Hezode C(2019)Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study Hepatol Res 49 617-626

[7]

Forns X(2017)Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression J Hepatol 67 1204-1212

[8]

Lee SS(2017)Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C J Hepatol 67 933-939

[9]

Valdes J(2020)Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment Hepatol Res 50 313-320

[10]

Tahata Y(2020)Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment Hepatol Res 50 1118-1127

← 1 2 3 4 5 6 7 8 9 10 →